Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verona Pharma Plc ADR (NQ: VRNA ) 38.18 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Verona Pharma Plc ADR < Previous 1 2 3 4 Next > Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent September 27, 2024 The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. Via Investor's Business Daily Exposures Product Safety Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesday September 11, 2024 Via Benzinga GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug September 06, 2024 GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks. Via Benzinga Top 3 Health Care Stocks That May Crash In August August 14, 2024 Via Benzinga 9 Health Care Stocks Whale Activity In Today's Session August 13, 2024 Via Benzinga Earnings Scheduled For February 29, 2024 February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. Via Benzinga Earnings Preview For Verona Pharma February 28, 2024 Via Benzinga Expert Ratings for Verona Pharma September 01, 2023 Via Benzinga Earnings Scheduled For August 3, 2023 August 03, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. Via Benzinga VRNA Stock Earnings: Verona Pharma Misses EPS for Q2 2024 August 08, 2024 VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Top 3 Health Care Stocks You May Want To Dump This Quarter July 30, 2024 Via Benzinga First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product June 27, 2024 The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. Via Benzinga Exposures Product Safety 10 Health Care Stocks Whale Activity In Today's Session June 25, 2024 Via Benzinga 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More June 24, 2024 Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. Via Benzinga 4 Analysts Have This to Say About Verona Pharma March 13, 2023 Via Benzinga Earnings Preview For Verona Pharma March 06, 2023 Via Benzinga Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday June 13, 2024 Via Benzinga Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks June 13, 2024 The companies are closing in on the finish line for two new COPD treatments. Via Investor's Business Daily VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024 May 09, 2024 VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 March 01, 2024 The healthcare sector is no slouch when it comes to top-performing growth stocks. Via The Motley Fool 3 Stocks That Could Be Monster Winners in 2024 December 30, 2023 Don't be surprised if these three stocks take off in the new year. Via The Motley Fool Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves December 29, 2023 In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion... Via Benzinga Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 26, 2023 Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... Via Benzinga Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal April 08, 2023 Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... Via Talk Markets Earnings Scheduled For November 2, 2023 November 02, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. Via Benzinga Earnings Scheduled For May 9, 2023 May 09, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. Via Benzinga Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday March 20, 2023 HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on... Via Benzinga 7 Biotech Stocks That Could Be the Next Big Thing March 15, 2023 Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. Via InvestorPlace PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday January 03, 2023 U.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Tuesday. Here are some big stocks recording losses in today’s session. Via Benzinga Why These 7 Healthcare Stocks Could Soar in 2023 January 02, 2023 These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. Via InvestorPlace < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
